HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: clinchem.2007.092411v1 54/1/209    most recent Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by McCudden, C. R. Articles by Grenache, D. G. Search for Related Content PubMed PubMed Citation Articles by McCudden, C. R. Articles by Grenache, D. G. Related Collections Clinical Case Studies

Persistent Low Concentration of Human Chorionic Gonadotropin in a Nonpregnant Woman

University of North Carolina School of Medicine, Department of Pathology and Laboratory Medicine, Chapel Hill, NC.

^aAddress correspondence to this author at: Department of Pathology, University of Utah Health Sciences Center, c/o ARUP Laboratories, 500 Chipeta Way, Salt Lake City, UT 84108. Fax 801-584-5207; e-mail david.grenache@path.utah.edu.

The first 300 words of the full text of this article appear below.

CASE

A 48-year-old woman presented for radio-iodine ablation therapy 3 months after undergoing a complete thyroidectomy performed for compressive goiter symptoms. The patient’s medical history included stage-3 follicular variant papillary thyroid cancer with no nodal involvement and no metastatic disease. A 6.5-cm papillary carcinoma had been identified and removed surgically. Despite this surgical treatment, 3 foci were detected by ¹²⁵I uptake testing, a finding that prompted the use of therapeutic ablation.

Because the patient reported 5 months of amenorrhea, a quantitative serum human chorionic gonadotropin (hCG) test (hCG+β assay, Roche Diagnostics) was performed to rule out pregnancy. The result was 7.0 IU/L (reference interval: <5.0) and the administration of 100 mCi I¹³¹ was cancelled owing to concern for a potential pregnancy. A repeat hCG test performed 4 days later was 7.0 IU/L. Follicle stimulating hormone (FSH) was determined to be 110 IU/L [reference intervals: 1.9–11.6 (follicular phase), 1.4–9.6 (luteal phase), and 21.5–131 IU/L (postmenopausal)].

DISCUSSION

hCG is produced by the trophoblastic tissue of the placenta and hence is a reliable marker for pregnancy. hCG also has clinical utility as a tumor marker because of its production by trophoblastic and nontrophoblastic neoplasms. Finally, hCG is also produced by the gonadotropic cells of the pituitary during the menopause (1)(2).

As demonstrated by this patient, a persistent low concentration of hCG is particularly perplexing. Such cases have 3 potential etiologies: (a) false-positive hCG due to interfering antibodies, (b) quiescent gestational trophoblastic disease, and (c) pituitary hCG.

false-positive HCG due to interfering antibodies
There are several reports of falsely increased hCG due to endogenously produced interfering antibodies (3). Interfering antibodies can be of 2 types: human antianimal antibodies (HAAA) or heterophile antibodies. HAAAs are directed toward a specific antigen and may be produced after treatment with therapeutic antibodies or exposure to animal antigens (4). . . . [Full Text of this Article]

quiescent gestational trophoblastic disease
pituitary HCG
diagnosis
resolution of case

points to remember

The following articles in journals at HighWire Press have cited this article:

				U.-H. Stenman Commentary Clin. Chem., January 1, 2008; 54(1): 213 - 214. [Full Text] [PDF]